A Phase 2 Study of the Insulin-Like Growth Factor-1 Receptor Inhibitor MK-0646 in Patients With Metastatic, Well-Differentiated Neuroendocrine Tumors
- Author
- REIDY-LAGUNES, Diane L1 ; VAKIANI, Efsevia2 ; SEGAL, Michal F1 ; HOLLYWOOD, Ellen M1 ; TANG, Laura H2 ; SOLIT, David B1 ; PIETANZA, M. Catherine1 ; CAPANU, Marinela3 ; SALTZ, Leonard B1
[1] Department of Medicine, Division of Solid Tumors, Memorial Sloan-Kettering Cancer Center, New York, New York, United States
[2] Department of Pathology, Memorial Sloan-Kettering Cancer Center, New York, New York, United States
[3] Department of Epidemiology and Biostatistics, Memorial Sloan-Kettering Cancer Center, New York, New York, United States - Source
Cancer. 2012, Vol 118, Num 19, pp 4795-4800, 6 p ; ref : 19 ref
- CODEN
- CANCAR
- ISSN
- 0008-543X
- Scientific domain
- Medical oncology
- Publisher
- Wiley-Blackwell, Hoboken, NJ
- Publication country
- United States
- Document type
- Article
- Language
- English
- Author keyword
- IGF-1 carcinoid insulin-like growth factor neuroendocrine tumors
- Keyword (fr)
- Cancérologie Essai clinique phase II Facteur croissance IGF1 Facteur croissance IGF Homme Inhibiteur Métastase Récepteur biologique Stade avancé Tumeur neuroendocrinienne Cancer Tumeur maligne
- Keyword (en)
- Cancerology Phase II trial Insulin like growth factor 1 Insulin like growth factor Human Inhibitor Metastasis Biological receptor Advanced stage Neuroendocrine tumor Cancer Malignant tumor
- Keyword (es)
- Cancerología Ensayo clínico fase II Factor crecimiento IGF1 Factor crecimiento IGF Hombre Inhibidor Metástasis Receptor biológico Estadio avanzado Tumor neuroendocrino Cáncer Tumor maligno
- Classification
- Discipline
- Tumours
- Origin
- Inist-CNRS
- Database
- PASCAL
- INIST identifier
- 26379530
Sauf mention contraire ci-dessus, le contenu de cette notice bibliographique peut être utilisé dans le cadre d’une licence CC BY 4.0 Inist-CNRS / Unless otherwise stated above, the content of this bibliographic record may be used under a CC BY 4.0 licence by Inist-CNRS / A menos que se haya señalado antes, el contenido de este registro bibliográfico puede ser utilizado al amparo de una licencia CC BY 4.0 Inist-CNRS
Access to the document
Install on your browser
DOI
10.1002/cncr.27459 
https://dx.doi.org/10.1002/cncr.27459
"O:13:\"PanistOpenUrl\":36:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000idc\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:18:\"10.1002\/cncr.27459\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:149:\"A Phase 2 Study of the Insulin-Like Growth Factor-1 Receptor Inhibitor MK-0646 in Patients With Metastatic, Well-Differentiated Neuroendocrine Tumors\";s:9:\"\u0000*\u0000jtitle\";s:6:\"Cancer\";s:9:\"\u0000*\u0000stitle\";s:6:\"Cancer\";s:7:\"\u0000*\u0000date\";s:4:\"2012\";s:9:\"\u0000*\u0000volume\";s:3:\"118\";s:8:\"\u0000*\u0000issue\";s:2:\"19\";s:8:\"\u0000*\u0000spage\";s:4:\"4795\";s:8:\"\u0000*\u0000epage\";s:4:\"4800\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0008-543X\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:13:\"REIDY-LAGUNES\";s:10:\"\u0000*\u0000aufirst\";s:7:\"Diane L\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:8:{i:0;s:16:\"VAKIANI, Efsevia\";i:1;s:15:\"SEGAL, Michal F\";i:2;s:18:\"HOLLYWOOD, Ellen M\";i:3;s:13:\"TANG, Laura H\";i:4;s:14:\"SOLIT, David B\";i:5;s:22:\"PIETANZA, M. Catherine\";i:6;s:16:\"CAPANU, Marinela\";i:7;s:16:\"SALTZ, Leonard B\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"CANCAR\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:149:\"A Phase 2 Study of the Insulin-Like Growth Factor-1 Receptor Inhibitor MK-0646 in Patients With Metastatic, Well-Differentiated Neuroendocrine Tumors\";s:8:\"\u0000*\u0000place\";s:11:\"Hoboken, NJ\";s:6:\"\u0000*\u0000pub\";s:15:\"Wiley-Blackwell\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"6\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Panist access
"O:12:\"IstexOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:18:\"10.1002\/cncr.27459\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:149:\"A Phase 2 Study of the Insulin-Like Growth Factor-1 Receptor Inhibitor MK-0646 in Patients With Metastatic, Well-Differentiated Neuroendocrine Tumors\";s:9:\"\u0000*\u0000jtitle\";s:6:\"Cancer\";s:9:\"\u0000*\u0000stitle\";s:6:\"Cancer\";s:7:\"\u0000*\u0000date\";s:4:\"2012\";s:9:\"\u0000*\u0000volume\";s:3:\"118\";s:8:\"\u0000*\u0000issue\";s:2:\"19\";s:8:\"\u0000*\u0000spage\";s:4:\"4795\";s:8:\"\u0000*\u0000epage\";s:4:\"4800\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0008-543X\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:13:\"REIDY-LAGUNES\";s:10:\"\u0000*\u0000aufirst\";s:7:\"Diane L\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:8:{i:0;s:16:\"VAKIANI, Efsevia\";i:1;s:15:\"SEGAL, Michal F\";i:2;s:18:\"HOLLYWOOD, Ellen M\";i:3;s:13:\"TANG, Laura H\";i:4;s:14:\"SOLIT, David B\";i:5;s:22:\"PIETANZA, M. Catherine\";i:6;s:16:\"CAPANU, Marinela\";i:7;s:16:\"SALTZ, Leonard B\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"CANCAR\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:149:\"A Phase 2 Study of the Insulin-Like Growth Factor-1 Receptor Inhibitor MK-0646 in Patients With Metastatic, Well-Differentiated Neuroendocrine Tumors\";s:8:\"\u0000*\u0000place\";s:11:\"Hoboken, NJ\";s:6:\"\u0000*\u0000pub\";s:15:\"Wiley-Blackwell\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"6\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Istex access
"O:16:\"UnpaywallOpenUrl\":35:{s:8:\"\u0000*\u0000email\";s:27:\"assistance-portail@inist.fr\";s:6:\"\u0000*\u0000fmt\";N;s:6:\"\u0000*\u0000doi\";s:18:\"10.1002\/cncr.27459\";s:6:\"\u0000*\u0000pii\";N;s:7:\"\u0000*\u0000pmid\";N;s:9:\"\u0000*\u0000atitle\";N;s:9:\"\u0000*\u0000jtitle\";N;s:9:\"\u0000*\u0000stitle\";N;s:7:\"\u0000*\u0000date\";N;s:9:\"\u0000*\u0000volume\";N;s:8:\"\u0000*\u0000issue\";N;s:8:\"\u0000*\u0000spage\";N;s:8:\"\u0000*\u0000epage\";N;s:8:\"\u0000*\u0000pages\";N;s:7:\"\u0000*\u0000issn\";N;s:8:\"\u0000*\u0000eissn\";N;s:9:\"\u0000*\u0000aulast\";N;s:10:\"\u0000*\u0000aufirst\";N;s:9:\"\u0000*\u0000auinit\";N;s:10:\"\u0000*\u0000auinitm\";N;s:5:\"\u0000*\u0000au\";N;s:9:\"\u0000*\u0000aucorp\";N;s:7:\"\u0000*\u0000isbn\";N;s:8:\"\u0000*\u0000coden\";N;s:8:\"\u0000*\u0000genre\";N;s:7:\"\u0000*\u0000part\";N;s:9:\"\u0000*\u0000btitle\";N;s:8:\"\u0000*\u0000title\";N;s:8:\"\u0000*\u0000place\";N;s:6:\"\u0000*\u0000pub\";N;s:10:\"\u0000*\u0000edition\";N;s:9:\"\u0000*\u0000tpages\";N;s:9:\"\u0000*\u0000series\";N;s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";N;}"
Unpaywall access
"O:16:\"EuropePMCOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:18:\"10.1002\/cncr.27459\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:149:\"A Phase 2 Study of the Insulin-Like Growth Factor-1 Receptor Inhibitor MK-0646 in Patients With Metastatic, Well-Differentiated Neuroendocrine Tumors\";s:9:\"\u0000*\u0000jtitle\";s:6:\"Cancer\";s:9:\"\u0000*\u0000stitle\";s:6:\"Cancer\";s:7:\"\u0000*\u0000date\";s:4:\"2012\";s:9:\"\u0000*\u0000volume\";s:3:\"118\";s:8:\"\u0000*\u0000issue\";s:2:\"19\";s:8:\"\u0000*\u0000spage\";s:4:\"4795\";s:8:\"\u0000*\u0000epage\";s:4:\"4800\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0008-543X\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:13:\"REIDY-LAGUNES\";s:10:\"\u0000*\u0000aufirst\";s:7:\"Diane L\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:8:{i:0;s:16:\"VAKIANI, Efsevia\";i:1;s:15:\"SEGAL, Michal F\";i:2;s:18:\"HOLLYWOOD, Ellen M\";i:3;s:13:\"TANG, Laura H\";i:4;s:14:\"SOLIT, David B\";i:5;s:22:\"PIETANZA, M. Catherine\";i:6;s:16:\"CAPANU, Marinela\";i:7;s:16:\"SALTZ, Leonard B\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"CANCAR\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:149:\"A Phase 2 Study of the Insulin-Like Growth Factor-1 Receptor Inhibitor MK-0646 in Patients With Metastatic, Well-Differentiated Neuroendocrine Tumors\";s:8:\"\u0000*\u0000place\";s:11:\"Hoboken, NJ\";s:6:\"\u0000*\u0000pub\";s:15:\"Wiley-Blackwell\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"6\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Europe PubMed Central access
"O:11:\"BaseOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:18:\"10.1002\/cncr.27459\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:149:\"A Phase 2 Study of the Insulin-Like Growth Factor-1 Receptor Inhibitor MK-0646 in Patients With Metastatic, Well-Differentiated Neuroendocrine Tumors\";s:9:\"\u0000*\u0000jtitle\";s:6:\"Cancer\";s:9:\"\u0000*\u0000stitle\";s:6:\"Cancer\";s:7:\"\u0000*\u0000date\";s:4:\"2012\";s:9:\"\u0000*\u0000volume\";s:3:\"118\";s:8:\"\u0000*\u0000issue\";s:2:\"19\";s:8:\"\u0000*\u0000spage\";s:4:\"4795\";s:8:\"\u0000*\u0000epage\";s:4:\"4800\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0008-543X\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:13:\"REIDY-LAGUNES\";s:10:\"\u0000*\u0000aufirst\";s:7:\"Diane L\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:8:{i:0;s:16:\"VAKIANI, Efsevia\";i:1;s:15:\"SEGAL, Michal F\";i:2;s:18:\"HOLLYWOOD, Ellen M\";i:3;s:13:\"TANG, Laura H\";i:4;s:14:\"SOLIT, David B\";i:5;s:22:\"PIETANZA, M. Catherine\";i:6;s:16:\"CAPANU, Marinela\";i:7;s:16:\"SALTZ, Leonard B\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"CANCAR\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:149:\"A Phase 2 Study of the Insulin-Like Growth Factor-1 Receptor Inhibitor MK-0646 in Patients With Metastatic, Well-Differentiated Neuroendocrine Tumors\";s:8:\"\u0000*\u0000place\";s:11:\"Hoboken, NJ\";s:6:\"\u0000*\u0000pub\";s:15:\"Wiley-Blackwell\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"6\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Base Search access
"O:12:\"ArXivOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:18:\"10.1002\/cncr.27459\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:149:\"A Phase 2 Study of the Insulin-Like Growth Factor-1 Receptor Inhibitor MK-0646 in Patients With Metastatic, Well-Differentiated Neuroendocrine Tumors\";s:9:\"\u0000*\u0000jtitle\";s:6:\"Cancer\";s:9:\"\u0000*\u0000stitle\";s:6:\"Cancer\";s:7:\"\u0000*\u0000date\";s:4:\"2012\";s:9:\"\u0000*\u0000volume\";s:3:\"118\";s:8:\"\u0000*\u0000issue\";s:2:\"19\";s:8:\"\u0000*\u0000spage\";s:4:\"4795\";s:8:\"\u0000*\u0000epage\";s:4:\"4800\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0008-543X\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:13:\"REIDY-LAGUNES\";s:10:\"\u0000*\u0000aufirst\";s:7:\"Diane L\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:8:{i:0;s:16:\"VAKIANI, Efsevia\";i:1;s:15:\"SEGAL, Michal F\";i:2;s:18:\"HOLLYWOOD, Ellen M\";i:3;s:13:\"TANG, Laura H\";i:4;s:14:\"SOLIT, David B\";i:5;s:22:\"PIETANZA, M. Catherine\";i:6;s:16:\"CAPANU, Marinela\";i:7;s:16:\"SALTZ, Leonard B\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"CANCAR\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:149:\"A Phase 2 Study of the Insulin-Like Growth Factor-1 Receptor Inhibitor MK-0646 in Patients With Metastatic, Well-Differentiated Neuroendocrine Tumors\";s:8:\"\u0000*\u0000place\";s:11:\"Hoboken, NJ\";s:6:\"\u0000*\u0000pub\";s:15:\"Wiley-Blackwell\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"6\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
arXiv access
